Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo de Braud

Showing results (111-120 of 497) with videos related to

Pageof 50
Sort By:
Drugs in R&D|August 13, 2017
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?Paolo Grassi, Elena Verzoni, Raffaele Ratta, et al.
Melanoma Research|December 7, 2018
Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experienceCarolina Cimminiello, Alice Indini, Lorenza Di Guardo, et al.
Oncology|November 8, 2014
Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patientsGiuseppe Procopio, Isabella Testa, Elena Verzoni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancerGiulia Veronesi, Paolo Scanagatta, Francesco Leo, et al.
Oncotarget|April 9, 2016
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studiesSara Pusceddu, Filippo De Braud, Giuseppe Lo Russo, et al.
Cancer Treatment Reviews|July 16, 2013
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disordersFrancesco Agustoni, Marco Platania, Milena Vitali, et al.
International Journal of Cancer|January 8, 2019
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trialsDominik Paul Modest, Fernando Rivera, Jean-Baptiste Bachet, et al.
Critical Reviews in Oncology/Hematology|July 31, 2007
Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five casesTommaso De Pas, Gianluca Spitaleri, Giancarlo Pruneri, et al.
Journal of the National Cancer Institute|August 31, 2007
Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialNicola Fazio, Roberto Biffi, Giuseppe Curigliano, et al.
International Journal of Cancer|December 10, 2019
A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancerCarolina Reduzzi, Marta Vismara, Marco Silvestri, et al.
Pageof 50

Showing results (111-120 of 497) with videos related to

Sort By:
Pageof 50
Drugs in R&D|August 13, 2017
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?Paolo Grassi, Elena Verzoni, Raffaele Ratta, et al.
Melanoma Research|December 7, 2018
Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experienceCarolina Cimminiello, Alice Indini, Lorenza Di Guardo, et al.
Oncology|November 8, 2014
Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patientsGiuseppe Procopio, Isabella Testa, Elena Verzoni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancerGiulia Veronesi, Paolo Scanagatta, Francesco Leo, et al.
Oncotarget|April 9, 2016
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studiesSara Pusceddu, Filippo De Braud, Giuseppe Lo Russo, et al.
Cancer Treatment Reviews|July 16, 2013
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disordersFrancesco Agustoni, Marco Platania, Milena Vitali, et al.
International Journal of Cancer|January 8, 2019
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trialsDominik Paul Modest, Fernando Rivera, Jean-Baptiste Bachet, et al.
Critical Reviews in Oncology/Hematology|July 31, 2007
Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five casesTommaso De Pas, Gianluca Spitaleri, Giancarlo Pruneri, et al.
Journal of the National Cancer Institute|August 31, 2007
Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialNicola Fazio, Roberto Biffi, Giuseppe Curigliano, et al.
International Journal of Cancer|December 10, 2019
A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancerCarolina Reduzzi, Marta Vismara, Marco Silvestri, et al.
Pageof 50